Optimize: Pain

Best evidence is for fibromyalgia, where tai chi eased symptoms more than aerobic exercise (Wang 2018, PMID 29563100), and it matched physical therapy for knee OA. Self-directed, low-cost, gentle enough for deconditioned and older readers. Condition scope: fibromyalgia and knee OA.

A continuous low-level heat wrap eased acute low back pain in the first days and is one of the cheapest, safest first moves. Condition scope: acute low back pain.

Improves back function in chronic low back pain and matches physical therapy over 12 weeks; the pain drop alone is modest (5 to 8 points on 100). Read it as a function-and-movement lever, self-directed. Condition scope: chronic low back pain.

Walkers with knee OA were less likely to develop new frequent knee pain over four years. The single claim is emerging, but it sits on top of a much stronger land-based-exercise-for-OA base (see completeness). Free, empower-first. Condition scope: knee OA.

Turmeric extract cut knee OA pain about 2 points on 10 and matched ibuprofen over 4 weeks with fewer stomach complaints. Many trials are small and some industry-linked, so hold it at moderate. Condition scope: knee OA.

Over 3 to 4 months, omega-3 modestly eased joint pain and cut painkiller use in inflammatory (rheumatoid/psoriatic) arthritis. A genuine adjunct, not a standalone. Condition scope: inflammatory arthritis.

About 600 mg a day is rated possibly effective for migraine prevention (AAN/AHS Level B). Note the honest null alongside it: magnesium did not help older adults' night leg cramps. Condition scope: migraine prevention (not cramps).

Self-applied, free, and low-risk; eased period pain, back-pain disability, and headache across many low-to-moderate quality trials. A reasonable adjunct when a reader wants a hands-on self-tool. Condition scope: menstrual, low back, headache, labor.

Targeted stretching helps a specific problem (a plantar-fascia stretch beats a calf stretch for heel pain). It does not reduce next-day muscle soreness, so keep the claim narrow. Condition scope: plantar fasciitis.

A small drop in chronic pain across 38 trials on low-quality evidence. Empower-first and safe; belongs with the broader psychological-therapy lever (see completeness).

Cut migraine frequency about 1.5 attacks a month across 5 small trials. Honest counterweight: it did nothing for confirmed statin muscle pain. Condition scope: migraine prevention (not statin myalgia).

Provider-delivered dextrose injection with real signals for knee OA, tennis elbow, and Osgood-Schlatter, but null for chronic low back pain. A situational option after self-directed measures. Condition scope: knee OA, lateral epicondylitis.

Injected ozone matched steroid or hyaluronic acid for knee OA and tracked with pain drops in disc herniation, across low-to-moderate evidence. Provider-delivered, situational. Condition scope: knee OA, lumbar disc.

Two reviews point to a medium-firm mattress for sleep and back pain. Cheap, sensible, weak evidence. Condition scope: low back pain.

Do NOT surface as start-here. Overall knee pain fell only about 0.5 cm on 10, short of the 0.9 cm patients notice, and against placebo directly the combination was no better. The larger effects come almost entirely from industry-funded, patented glucosamine-sulfate trials (about ten times bigger than independent trials). Honest read: mostly no meaningful benefit; a low-risk try for moderate-to-severe knee OA if a reader wants it. Condition scope: knee OA.

Fibromyalgia pain fell about 29% vs 18% on placebo in a 31-woman RCT plus a 10-woman pilot. Small but consistent and cheap; a reasonable try-it option for fibromyalgia. Condition scope: fibromyalgia.

The signal is from pain reprocessing therapy (Ashar 2022), which left about two-thirds of chronic back pain patients pain-free versus placebo and usual care. Promising for nociplastic/centralized back pain; DNRS itself is the more marketed cousin. Condition scope: chronic primary back pain.

Improved knee OA function and eased pain in about half the trials, on low-quality evidence. Worth watching, not a headline. Condition scope: knee OA.

Eases knee OA, neck, and tendon pain but only at an adequate wavelength and dose, which most home devices do not disclose. Condition scope: knee OA, neck, tendinopathy.

A small, uneven cut in OA pain, possibly below what patients notice, and no better than sham for fibromyalgia. Condition scope: knee OA.

Beats no treatment for neck and low back pain, but against sham cupping the advantage disappears (SMD -0.27) and no review rated the evidence high quality. Read the benefit as largely context/expectation-mediated. Condition scope: neck, low back.

Signals for knee OA, chronic low back pain, and period pain across many low-quality trials. Condition scope: knee OA, low back, dysmenorrhea.

A course eased rheumatoid arthritis pain and disease activity across 257 patients. Small trials, adjunct only. Condition scope: rheumatoid arthritis.

NMES eased knee OA pain by 8 to 12 weeks but built no extra strength. A modest adjunct. Condition scope: knee OA.

One open-label trial of 60 women eased fibromyalgia pain. No blinding, high cost, weak base. Condition scope: fibromyalgia.

Lowered TNF and eased rheumatoid arthritis in 17 patients. First-in-human scale. Condition scope: inflammatory arthritis.

Modest knee OA relief in four small trials of 138 patients. Expensive, unstandardized, provider-delivered. Condition scope: knee OA.

Pain fell versus a passive comparator but not versus another active practice, on low-quality evidence. Condition scope: general.

CBD on its own did not clearly relieve chronic pain beyond placebo. Kept honestly as a no-effect finding, not a lever.